Compounded vs Brand Semaglutide: What Actually Differs and What the FDA Changed

The one-sentence version. Brand semaglutide is an FDA-approved product reviewed before marketing; compounded semaglutide is a preparation that FDA has not reviewed or approved, was broadly permitted only while semaglutide sat on the FDA shortage list, and lost that permission in 2025.

This is the head-to-head comparison. Transition guidance for Michigan patients is in FDA compounded GLP-1 ban; background on the restriction is in why GLP-1 compounding was banned.

What a Compounded Preparation Actually Is

Compounding means combining, mixing or altering drug ingredients to create a medication tailored to one patient — removing a dye someone reacts to, turning a tablet into a liquid, making a strength nobody manufactures.

The fact most marketing obscures: compounded drugs have not been reviewed or approved by FDA. They do not go through FDA premarket review for safety and effectiveness, and they are not generics — FDA has been explicit that they "are not the same as generic drugs, which are FDA-approved" (FDA press announcement, March 3, 2026). That does not make compounding illegitimate; it has a long-standing place in medicine. It does mean the comparison is not "same drug, cheaper." It is a different regulatory category with a different oversight structure behind it.

503A Pharmacies vs 503B Outsourcing Facilities

Federal law creates two compounding pathways, named for the sections of the Federal Food, Drug, and Cosmetic Act that create them. Patients are rarely told which one their product came from, and it matters.

503A: traditional compounding pharmacies. State-licensed pharmacies. Under section 503A, drugs "must be compounded based on the receipt of valid patient-specific prescriptions" (FDA, Compounding Laws and Policies). They are not subject to current good manufacturing practice (CGMP) requirements, and state boards of pharmacy have primary responsibility for day-to-day oversight (FDA Q&A).

503B: outsourcing facilities. Created by the Drug Quality and Security Act in 2013, after a fungal meningitis outbreak traced to contaminated compounded injections. A 503B facility registers with FDA, is subject to CGMP, is inspected by FDA on a risk-based schedule, and may distribute against a patient-specific prescription or against a provider order "that is not for an identified individual patient (e.g., for office stock)" (FDA).

So 503B is held to manufacturing-style standards and federal inspection; 503A is not. Neither produces an FDA-approved product.

The Shortage List Is the Switch That Turns Compounding On and Off

This is the mechanism almost nobody explains, and it is the whole story. Both sections prohibit compounding a drug that is "essentially a copy of a commercially available drug product" — 503A(b)(1)(D) and 503B(d)(2) — and FDA has issued formal guidance on what counts (FDA Guidance for Industry).

A drug on FDA's shortage list is not considered commercially available. That single definitional fact opened the door: while semaglutide sat on the shortage list, compounders could make copies at scale without running into the essentially-a-copy prohibition. For 503B facilities there is a second door — the 503B Bulks List, a list of bulk substances FDA has determined there is a clinical need to compound from. Semaglutide has never been on it.

When the shortage resolves, the door closes — not because of a safety recall, but because the legal precondition disappeared.

What Changed, and Exactly When

FDA published the timeline itself (FDA clarifies policies for compounders as national GLP-1 supply begins to stabilize):

• December 19, 2024 — FDA determined the tirzepatide injection shortage was resolved.
• February 18, 2025 — end of FDA's enforcement discretion for 503A compounding of tirzepatide.
• February 21, 2025 — FDA determined the semaglutide injection shortage was resolved.
• March 19, 2025 — end of enforcement discretion for 503B tirzepatide.
• April 22, 2025 — end of enforcement discretion for 503A semaglutide.
• May 22, 2025 — end of enforcement discretion for 503B semaglutide.

FDA then moved to make the 503B position permanent. On April 30, 2026 it proposed excluding semaglutide, tirzepatide and liraglutide from the 503B Bulks List, on the determination that there is no clinical need for outsourcing facilities to compound them from bulk substance. Commissioner Marty Makary framed it as: "When FDA-approved drugs are available, outsourcing facilities cannot lawfully compound using bulk drug substances unless there is a clear clinical need" (FDA press announcement, April 30, 2026). The proposal published in the Federal Register on May 1, 2026 (doc. 2026-08552), and the comment period was extended to July 30, 2026 (Federal Register, June 26, 2026).

Where that leaves things as of 17 August 2026. Semaglutide is off the shortage list and is not on the 503B Bulks List, so neither pathway supports routine, large-scale compounding. The April 2026 proposal would make that permanent for 503B facilities; at the time of writing we could not confirm a final FDA determination, and the comment period closed only weeks ago. Regulatory positions and litigation move — check the FDA pages linked above, or ask us, rather than relying on this paragraph six months from now.

Separately, on March 3, 2026 FDA announced warning letters to 30 telehealth companies for false or misleading claims — including implying their compounded products were equivalent to FDA-approved drugs, and advertising under their own branding without disclosing who actually compounded the product (FDA).

What Is the Same, and What Genuinely Differs

What is the same. If a compounded preparation genuinely contains semaglutide base at the labelled strength, the pharmacology is the pharmacology — a GLP-1 receptor agonist with a roughly week-long half-life. The mechanism does not care which building it was prepared in.

1. The evidence attaches to the approved product. According to PubMed, the outcome data patients have heard about come from trials of the approved formulation. In STEP 1, 1,961 adults on once-weekly semaglutide 2.4 mg lost a mean 14.9% of body weight over 68 weeks versus 2.4% on placebo (Wilding et al., NEJM 2021, PMID 33567185, DOI). In SELECT, among 17,604 patients with cardiovascular disease and no diabetes, the primary cardiovascular composite occurred in 6.5% on semaglutide versus 8.0% on placebo (HR 0.80) (Lincoff et al., NEJM 2023, PMID 37952131, DOI). No compounded preparation carries its own outcome trial.

2. Manufacturing oversight. Brand product is made under CGMP with batch release testing and stability data. A 503B facility is also under CGMP and FDA inspection; a 503A pharmacy is not.

3. Supply reliability. A supply resting on a regulatory permission already withdrawn once is not something to plan a two-year treatment course around.

4. What the safety-signal data show. An analysis of the FDA Adverse Event Reporting System from 2018 to 2024 found 707 compounded-product reports among 81,078 GLP-1 reports. Compounded products showed higher reporting odds ratios for preparation errors (48.92; 95% CI 12.63–189.6), contamination (19.00; 4.24–85.03) and hospitalisation (2.35; 1.94–2.83) — but, notably, lower odds of dosing errors (0.24; 0.17–0.32) (McCall et al., Expert Opin Drug Saf 2025, PMID 40285721, DOI). We report the finding that cuts against the narrative as well as the one that supports it. Disproportionality analysis of a voluntary database shows reporting patterns, not incidence.

5. The active ingredient may not be the one in the approved drug. Some products have been made with salt forms. FDA's position is direct: "these salt forms, including semaglutide sodium and semaglutide acetate, are different active ingredients than are used in the approved drugs" (FDA's Concerns with Unapproved GLP-1 Drugs Used for Weight Loss).

The Dosing-Unit Problem, Which Is the Part That Actually Hurts People

Brand semaglutide comes in a pen calibrated in milligrams: you dial a dose. Compounded semaglutide has typically come as a multiple-dose vial at a pharmacy-chosen concentration, drawn with a separately supplied syringe — often a U-100 insulin syringe marked in units, not milligrams. Three measurement systems end up in one conversation.

FDA's alert of July 26, 2024 describes what follows. Patients instructed to draw a 5-unit (0.05 mL) dose drew 50 units — a tenfold error. Reported cases included prescriptions written for 25 units instead of 5, and 20 instead of 2. Patients administered five to 20 times the intended dose, and some required medical attention or hospitalisation (FDA).

According to PubMed, a poison control centre case series makes the same point: three patients, two with tenfold errors, one given a vial and syringes with no pharmacist counselling. The authors concluded that vials of compounded semaglutide lack the safety features of prefilled manufactured pens and allow for large overdoses (Lambson et al., J Am Pharm Assoc 2023, PMID 37392810, DOI).

If you are on any vial-and-syringe preparation: know your concentration in mg/mL, your dose in milligrams, and the corresponding volume in millilitres. Write all three down, and do not accept a dose expressed only in "units" without the conversion. That habit prevents the most common serious error in this category.

Cost, Stated Carefully

Cost was the honest reason many patients chose compounded product, and it deserves a straight answer. The gap has narrowed. On November 17, 2025 Novo Nordisk announced a reduced self-pay price for Wegovy and Ozempic through its direct pharmacy channel — $349 per month, with a $199 introductory price for the first two doses of the 0.25 mg and 0.5 mg strengths running through March 31, 2026 (Novo Nordisk news release). That window has closed and pricing programmes change frequently, so verify current pricing with the manufacturer before budgeting and treat any figure on any clinic website — including this one — as potentially stale. Insurance coverage varies widely by plan and indication.

Telling a Legitimate Pharmacy From an Unsafe Source

Framed as things to check, not things to fear.

• It is a state-licensed pharmacy. Verify through FDA's BeSafeRx or the National Association of Boards of Pharmacy list at safe.pharmacy.
• A prescription is required and a real clinician is involved. No prescription, no clinician, no questions about your history — the clearest signal to walk away.
• Nothing is labelled "for research use only." FDA has warned that companies illegally sold unapproved semaglutide, tirzepatide or retatrutide falsely labelled "for research purposes" while selling to consumers with dosing instructions (FDA). This includes anything you reconstitute yourself from powder.
• The active ingredient is semaglutide, not a salt form.
• The ingredient source is traceable. On September 5, 2025 FDA launched a "green list" import alert covering GLP-1 active pharmaceutical ingredients from facilities it has inspected or evaluated; APIs from other sources face detention without physical examination (FDA).
• Marketing does not claim brand equivalence, and you are told who compounded it. Both were cited in FDA's March 2026 warning letters.

For scale: as of November 30, 2024 FDA had received over 392 adverse event reports for compounded semaglutide and 215 for compounded tirzepatide (FDA). Voluntary reporting undercounts, and counts are not rates.

How We Handle This at Arbour Longevity

Our role is clinician-supervised prescribing and monitoring: we assess whether GLP-1 therapy is appropriate for you at all, prescribe within the current regulatory framework, and monitor you on it. We do not solve regulatory problems with workarounds, and we will say plainly when a route is not available.

For someone arriving on a compounded preparation, that means confirming what you are actually taking — the concentration in mg/mL and the true milligram dose, which is often not what the patient believes; reviewing metabolic labs so the decision rests on what treatment has accomplished, not the scale alone; mapping options including cost and coverage; and, if a switch is appropriate, titrating deliberately.

More on our approach: semaglutide, GLP-1 therapy, weight loss shots and medical weight loss in Ann Arbor.

Frequently Asked Questions

Is compounded semaglutide the same drug as Ozempic or Wegovy?

Not in the regulatory sense, and sometimes not chemically either. Compounded preparations have not been reviewed or approved by FDA and are not generics (FDA, March 3, 2026). Some have used salt forms FDA considers different active ingredients altogether (FDA).

Is compounded semaglutide illegal now?

The broad, shortage-based permission ended in 2025 — April 22, 2025 for 503A pharmacies and May 22, 2025 for 503B facilities (FDA). Compounding for a documented individual clinical need the approved product cannot meet is a narrow and separate question, and a clinical determination rather than a preference. Cost alone does not create that need. This area is actively moving, so confirm the current position rather than relying on any article's snapshot.

I have been on compounded semaglutide and it worked. Do I have to start over?

No. Treatment history is not erased by a formulation change. The work is establishing what you are actually taking in milligrams, reviewing your labs, and titrating deliberately rather than assuming the numbers map one to one. That is a planning conversation, not a restart.

Why do I dose in "units" on the compounded version and milligrams on the pen?

Because vials are filled at a pharmacy-chosen concentration and drawn with insulin syringes marked in units. That mismatch is the documented source of tenfold errors — patients drawing 50 units where 5 units (0.05 mL) was intended (FDA, July 26, 2024). Always know your mg/mL, your milligram dose, and the millilitre volume that corresponds to it.

Is compounded semaglutide dangerous?

That is the wrong frame. The identifiable risks are specific and mostly avoidable: measurement errors from vial-and-syringe dosing, ingredient sourcing you cannot verify, salt forms that are not the approved active ingredient, and sources with no clinician involvement. The FAERS analysis above found higher reporting odds for preparation errors, contamination and hospitalisation, and lower reporting odds for dosing errors (PMID 40285721, DOI) — reporting patterns, not incidence rates.

How do I check whether a pharmacy is legitimate?

Confirm it is state-licensed, requires a prescription, and involves a real clinician. Verify through FDA's BeSafeRx or the NABP list at safe.pharmacy. Anything sold without a prescription, labelled "for research use only", or requiring you to reconstitute powder yourself sits outside the legitimate supply chain.

Could compounding become permitted again?

It could, if a genuine shortage were declared again — that is exactly how the mechanism works. The April 30, 2026 proposal would close the separate 503B bulks pathway permanently (FDA). We could not confirm a final determination as of 17 August 2026.

Talking It Through in Ann Arbor

Gandhi Bhattarai, FNP-BC, PMHNP-BC, Anti-Aging/Functional Medicine BC is a triple board certified nurse practitioner. We are at 2217 Packard St #15, in the Eastover Professional Center, Ann Arbor, MI 48104, open Thursday through Monday, 10am to 7pm, closed Tuesday and Wednesday. Parking is free and directly outside — no meters and no structure. Suite 15 is down a flight of stairs; if stairs are difficult for you, please call (734) 436-3357 before visiting.

Call (734) 436-3357 or book your first visit. The first visit is $35, applied toward your treatment plan. Cash pay, HSA and FSA accepted.

Clinical information on this page is drawn from articles retrieved from PubMed and from primary FDA sources, and is provided for education. It is not medical advice, not legal advice, not a diagnosis, and not a promise of any individual result. Regulatory status reflects sources verified on 17 August 2026 and may have changed since.